ABL Bio

ABL Bio Equity

The The Equity of ABL Bio (298380.KQ) as of Nov 3, 2026 is 154.72 B KRW. In the previous year, The Equity was 167.28 B KRW — a change of -7.51% (lower).

Equity

154.72 BKRW

YoY

-7.51%

Last updated:

In 2025, ABL Bio's equity was 154.72 B KRW, a -7.51% increase from the 167.28 B KRW equity in the previous year.

The ABL Bio Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
156.96 B KRW
Jan 1, 2019
132.01 B KRW
Jan 1, 2020
90.66 B KRW
Jan 1, 2021
55.95 B KRW
Jan 1, 2022
69.51 B KRW
Jan 1, 2023
74.08 B KRW
Jan 1, 2024
167.28 B KRW
Jan 1, 2025
154.72 B KRW
The ABL Bio Equity history
YEAREquityYoY
154.72 BKRW-7.51%
167.28 BKRW+125.81%
74.08 BKRW+6.57%
69.51 BKRW+24.24%
55.95 BKRW-38.29%
90.66 BKRW-31.32%
132.01 BKRW-15.90%
156.96 BKRW-282.61%
-85.96 BKRW+610.43%
-12.10 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ABL Bio Stock analysis

What does ABL Bio do? ABL Bio, Inc. develops therapeutic drugs for immuno-oncology and neurodegenerative diseases, focusing on anti-angiogenesis antibodies, anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, and antibody-drug conjugates (ADCs). The company generates revenue through the development and commercialization of these advanced biopharmaceutical products, targeting pharmaceutical companies and research institutions seeking innovative treatments for cancer and neurological disorders. Its product portfolio addresses unmet medical needs in oncology and neurology, with a focus on next-generation antibody-based therapies. The company's pipeline includes multiple proprietary drug candidates designed to enhance treatment efficacy and patient outcomes in complex disease areas. ABL Bio, Inc. serves pharmaceutical companies and research institutions as its primary customers, providing them with proprietary antibody technologies and drug candidates for further development and potential commercialization. The company's products are positioned within the immuno-oncology and neurodegenerative disease segments, where demand for targeted therapies is growing. By developing novel antibody-based treatments, ABL Bio aims to capture market share in high-growth therapeutic areas, leveraging its expertise in bispecific and dual-targeting antibody platforms to address complex medical challenges. ABL Bio is one of the most popular companies on Eulerpool.

Equity Details

Analyzing ABL Bio's Equity

ABL Bio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ABL Bio's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ABL Bio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ABL Bio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ABL Bio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ABL Bio stock

The Equity of ABL Bio is 154.72 B KRW in 2025.

The Equity of ABL Bio changed from 167.28 B KRW to 154.72 B KRW, representing a -7.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity ABL Bio since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's ABL Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — ABL Bio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — ABL Bio